LEXINGTON, Mass.--(BUSINESS WIRE)--July 25, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX - News) today announced that it has completed the double-blind, placebo-controlled, single-dose Phase I/II clinical trial of the intravenous (IV) formulation of zileuton in patients with asthma and is currently analyzing the data. Dosing was initiated in February 2006 and Critical Therapeutics expects to report preliminary results from this trial later this quarter. The Company is developing zileuton IV initially for use in patients who suffer acute exacerbations of asthma. According to the Centers for Disease Control and Prevention’s National Center for Health Statistics, asthma resulted in approximately 1.8 million emergency room visits in the United States in 2003.
